ETV6-NTRK2 fusion

After pursuing other alternative treatments, including chemotherapy (ie, carboplatin, etoposide, capecitabine, temozolomide, and paclitaxel), everolimus, and atezolizumab, she returned with significant progression, including innumerable subcutaneous nodules, left pleura metastasis, multiple bone metastases, and brain metastases. To date, she has maintained sustained benefit for at least 1 year from initiation of entrectinib. Here, we present the first case of a female patient with metastatic AC harboring the ETV6-NTRK2 fusion, and successfully treated with entrectinib, providing evidence for the application of entrectinib in patients with NTRK-positive AC, and underscoring the critical role of molecular profiling for such cases.

In September 2021, Cranial MRI showed brain metastases and the patient received paclitaxel monotherapy for 1 cycle, followed by self-administered temozolomide and capecitabine for 3 cycles...In fourth-line therapy, the patient underwent paclitaxel liposome and everolimus for 7 months...The patient underwent etoposide, carboplatin and atezolizumab for 2 cycles, but in February/2023, a subcutaneous mass was developed in the right chest wall, pathological results suggested again atypical carcinoid by surgical excision, and next generation sequencing (NGS) demonstrated ETV6-NTRK2 gene fusion... We present the case of a patient with lung atypical carcinoid with NTRK gene fusion on re-biopsy after multiple line therapy failure of platinum-based chemotherapy , targeted therapy, even immunotherapy . Entrectinib seventh line of therapy, achieved complete response, which emphasizing the efficacy of this selective NTRK kinase inhibitor on this rare neuroendocrine tumor with NTRK fusion.